.......
"Bosutinib had manageable toxicity and acceptable tolerability, with adverse events distinct from that of other tyrosine kinase inhibitors.
Adverse events were primarily characterized by early-onset gastrointestinal events that were low grade, transient, and manageable."
Extrait de Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
Journal Blood - décembre 2013
.......
Voir aussi Bosulif(bosutinib)
.......